Cannabidiol (CBD) is a cannabis extract with remarkable medicinal properties, and for the past few years, it has kept the world enthralled. It is often confused for THC (delta-9 tetrahydrocannabinol), the component responsible for cannabis’s famous high, but CBD is non-psychoactive, and it doesn’t make users high. Instead, the compound acts as a potent and versatile medicine, working against a variety of conditions ranging from anxiety and high blood pressure to chronic pain and rare childhood epilepsies. However, it has only been researched to a limited degree, and there is still a lot about CBD that we still don’t know. Results from a recent study show that CBD may also help women seeking relief from endometriosis-related pain.
The study was presented at the 2019 American Association of Gynecologic Laparoscopists (AAGL) Global Congress in Vancouver, Canada. Its primary goal was quantifying the rate of cannabis and cannabidiol use among endometriosis patients, as well as its effectiveness. The REDCap Survey was conducted online, and participants were invited through email to answer a list of 50 to 75 questions based on branching logic. Most of the participants were either identified through a mailing list for the Endometriosis Association or an ICD-10 code for endometriosis diagnosis at a clinic.
“Our participation was very different between our two groups. The invitation stressed that this was an anonymous survey, but I think there’s still a taboo around this topic,” says Anna Reinert, MD, the presenting author of the study. Two hundred forty people from the Endometriosis Association replied, and 77 (32.1%) of them reported having tried cannabis before, with 52 of the 72 saying the cannabis was very or moderately effective. Sixty-seven people said they had tried CBD, and for 50% of them, it was very or moderately effective at reducing pain. Fifty-seven patients from the clinic had tried CBD in the past, and 64% of them said it had been very or moderately effective.
Over the years, more people have turned to CBD to help manage their pains. A study published in the European Journal found that CBD reduced inflammation and pain in rats and that it might also be applicable in humans. Another report stated that there was substantial evidence that cannabidiol could be used to manage chronic pain in adults.
However, Dr. Reinert says that “further research is needed to explore the potential benefits and clarify the limitations and risks of the use of cannabis for the management of chronic pelvic pain and endometriosis.”
Such research findings make analysts to believe that industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) are more than justified to strongly affirm that cannabidiol has immense health benefits that could even take decades to fully understand.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.